Enter multiple symbols separated by commas

Pfizer Earnings By the Numbers

Pfizer, the world's largest drugmaker, is scheduled to repo

Pfizer headquarters in New York City.
Getty Images
Pfizer headquarters in New York City.

rt fourth-quarter results before the opening bell on Wednesday, February 3.

The consensus First Call EPS estimate stands at $0.50 compared to last year's gain of $0.65, while revenue is expected to increase by 29.7% to $15.97 billion.

What follows are some facts and figures on how Pfizer shares traded in the most recent earnings reports.


  • Beat revenue estimates for 4 of the past 8 quarters

  • Beat EPS estimates for 7 of the past 8 quarters

  • Beat annual EPS estimates for 3 of the past 5 years

  • Dollar impact? In 2008, 58% of revenue was derived from outside the United States

  • Pfizer shares are up 3% in 2010, and 49% since the March low

  • Competitors' Performance in 2010: Merck +5%, Novartis -0.7%, Amgen +4% and Biogen Idec +0.8%

  • Pfizer shares hit a new 52-week high of $20.36 on January 20, 2010

  • The company's shares are trading 0.8% above their 50-day moving average

Stock Performance By The Numbers

  • In the past 8 quarters, Pfizer shares rose 1.57%, on average, the day before the company reported its quarterly results
  • Pfizer shares have a bearish trend that peaks 4 days after earnings. It has declined 8 times after the past 10 earnings reports, posting an overall average loss of 2% (MarketHistory.com)

S&P Healthcare Sector:

  • Best performing sector so far in 2010, up 0.9%
  • Leaders year-to-date: Humana +11%, Genzyme +10.6% and Gilead Sciences +10.5%
  • Losers year-to-date: Forest Laboratories -8%, Allergan -8% and Waters Corp. -7.7%

Earning Estimates Source: CNBC & Thomson Reuters